Nanopath
PrivateLast Round
Series B
Nov 10, 2026
Total Funding Raised
$39M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Nanopath operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in November 2026.
Nanopath is a diagnostic equipment company that has developed a molecular diagnostic platform designed to enable point-of-care disease diagnosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanopath Comparables
Compare Nanopath with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VedaBio | 86% | |
| Rover Diagnostics | 82% | |
| Alveo Technologies | 82% |
For institutional investors. Book with your work email.
Nanopath Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 10, 2026 | ||||
| Grant | May 21, 2024 | ||||
| Series A | Aug 9, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nanopath Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series A, Series B |
| NIH RADx | Grant |
| GingerBread Capital | Series A, Series B |
| Norwest Venture Partners | Series A, Series B |
| National Institutes of Health (NIH) | Grant |
| Alumni Ventures | Series A |
| Alumni Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$25M round led by Norwest Venture Partners and SV Health Investors.
- Jul 27, 2026
Open roles increased to 45, 3x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 10, 2026
Nanopath Inc. receives more than $52K through the Internship Challenge to support 10 interns in Massachusetts since 2022.
- increases_headcount_byNov 10, 2026
Nanopath Inc. receives a $288,000 Tax Incentive award in 2026 to support the creation of 12 new jobs as it expands its team in Massachusetts.
- hiresNov 10, 2026
Catherine Kiani, J.D., Managing Partner at Elderberry Ventures, joins the Nanopath Inc. Board as an Observer as part of the financing on Nov 10th '26 in Massachusetts.
- hiresNov 10, 2026
Nanopath Inc. names Mindy Nye, Vice President, Labcorp Diagnostics, as a Board Observer as part of its $25 million Series B financing in Massachusetts on Nov 10th '26.
- receives_financingNov 10, 2026
Nanopath Inc. receives $25M Series B financing, co-led by Norwest and SV Health Investors' MedTech Convergence Fund with participation from Labcorp Venture Fund and other investors, to fund its FDA 510(k) study for a point-of-care vaginitis test and prepare for proposed commercialization in Massachusetts on Nov 10th '26.
For institutional investors. Book with your work email.
Nanopath Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nanopath's valuation, stock price, and market status.
Is Nanopath a public or private company?
Nanopath is a private company.
What is the current stock price of Nanopath?
Nanopath is a private company, so its shares have no public market price. Caplight tracks Nanopath's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanopath worth (valuation)?
Valuation information for Nanopath is not publicly available.
Can I buy Nanopath stock?
Nanopath shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanopath's last funding round?
Nanopath's most recent funding round was Series B on November 10, 2026.
Who are the main investors in Nanopath?
Key investors in Nanopath include SV Health Investors, Norwest Venture Partners.
Will Nanopath IPO soon?
No public IPO plans have been announced for Nanopath.
How can I track Nanopath secondary market activity?
Caplight tracks bids, offers, and trades in Nanopath's shares on secondary markets.